Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma KARMMA-2

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug bb2121 in combination with lenalidomide maintenance when given to participants with relapsed and refractory or high-risk multiple myeloma. 

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is organized into five main groups, or cohorts. Depending on when their myeloma was diagnosed, and the type and quantity of treatment previously received, participants will be assigned to one of the cohorts. Cohorts 1 and 3 are accepting patients. 

Participants in all cohorts are planned to receive bb2121 alone or bb2121 in combination with lenalidomide. The study can be broken down into a few different parts. 

Before bb2121 administration - During this part of the trial, participants will be screened for eligibility, undergo a collection of their T cells (leukapheresis) to make into investigational drug bb2121 and undergo other evaluations before the treatment part. Depending on the cohort they are placed in , participants may receive Lenalidomide or another approved treatment as anti-myeloma therapy while waiting for their T cells to be processed. 

bb2121 administration - During this part of the trial, participants will receive lymphodepleting chemotherapy and investigational drug bb2121. The lymphodepleting chemotherapy is used to remove some immune cells, making space for the investigational bb2121 T cells to grow in the body, and to increase the chances of the body’s ability to accept the investigational bb2121 T cells. When receiving investigational drug bb2121, participants will be hospitalized for approximately 14 days so that the study doctors can monitor closely for side effects. 

After bb2121 administration - Once discharged from the hospital, participants will need to stay within a 30 minute drive from the treating hospital and have a dedicated caregiver staying with them for the remainder of the 30 days following investigational drug bb2121 treatment. Participants will need to visit the study site for follow-up monthly for the first 6 months, then every 3 months for the first two years. The study doctor may prescribe a maintenance anti-myeloma therapy Lenalidomide during this time.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • meet prior line of therapy criteria. 
    • Participants in cohort 1 must have had 3 or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and an anti-CD38 antibody.
    • Participants in cohort 3 must have previously had an autologous stem cell transplant, including a proteasome inhibitor and immunomodulatory drug induction.
    • do not have central nervous system involvement of your myeloma.
    • do not have nonsecretory multiple myeloma.
    • have adequate bone marrow, cardiac, kidney, and lung function as described in the trial criteria. 
    • Suboptimal response to autologous stem cell transplant.

Additional eligibility criteria apply and can be explained by the study doctor. 

Additional Trial Information

Phase 2

Enrollment: 265 patients (estimated)

View More

Trial Links

Read the latest news and updates on this trial.

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 05, 2020

Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) in updated findings presented from the phase 1 CRB-401 trial (NCT02658929).

Read more

Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

June 01, 2018

Celgene Corporation and bluebird bio, Inc. today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple myeloma.

Read more

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Moffitt Cancer Center Magnolia Campus

Tampa, FL

Open and Accepting


Winship Cancer Institute Emory University

Atlanta, GA

Open and Accepting


Massachusetts General Hospital

Boston, MA

Recruitment on Hold

Beth Israel Deaconess Medical Center

Boston, MA

Recruitment on Hold


Alvin J. Siteman Cancer Center Washington University Medical Campus

St. Louis, MO

Open and Accepting


New Jersey

New York

Mount Sinai Hospital Tisch Cancer Institute

New York, NY

Open and Accepting

North Carolina

Atrium Health's Levine Cancer Institute - Charlotte (Main) Atrium Health

Charlotte, NC

Open and Accepting



MD Anderson Cancer Center The University of Texas

Houston, TX

Recruitment on Hold


Swedish Cancer Institute - Cherry Hill Campus

Seattle, WA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors